Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiya Yu

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Cancer Immunology, Immunotherapy : CII|February 10, 2011
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cellsShicheng Yang, Luca Gattinoni, Gattinoni Luca, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cellsClaudia Wrzesinski, Chrystal M Paulos, Andrew Kaiser, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
The Journal of Clinical Investigation|August 18, 2004
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of toleranceZhiya Yu, Marc R Theoret, Christopher E Touloukian, et al.
The Journal of Clinical Investigation|June 3, 2005
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsLuca Gattinoni, Christopher A Klebanoff, Douglas C Palmer, et al.
Plos One|May 16, 2014
Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingYun Ji, Natalie Abrams, Wei Zhu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2010
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinaseTimothy L Frankel, William R Burns, Peter D Peng, et al.
JCI Insight|April 20, 2018
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine modelBenjamin Y Jin, Tracy E Campbell, Lindsey M Draper, et al.
Journal for Immunotherapy of Cancer|September 27, 2023
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomicsCatherine M Ade, Matthew J Sporn, Sudipto Das, et al.
European Journal of Immunology|July 20, 2024
Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Malcolm J W Sim, Ken-Ichi Hanada, Zachary Stotz, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Cancer Immunology, Immunotherapy : CII|February 10, 2011
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cellsShicheng Yang, Luca Gattinoni, Gattinoni Luca, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cellsClaudia Wrzesinski, Chrystal M Paulos, Andrew Kaiser, et al.
The Journal of Clinical Investigation|October 28, 2010
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDhanalakshmi Chinnasamy, Zhiya Yu, Marc R Theoret, et al.
The Journal of Clinical Investigation|August 18, 2004
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of toleranceZhiya Yu, Marc R Theoret, Christopher E Touloukian, et al.
The Journal of Clinical Investigation|June 3, 2005
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsLuca Gattinoni, Christopher A Klebanoff, Douglas C Palmer, et al.
Plos One|May 16, 2014
Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencingYun Ji, Natalie Abrams, Wei Zhu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2010
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinaseTimothy L Frankel, William R Burns, Peter D Peng, et al.
JCI Insight|April 20, 2018
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine modelBenjamin Y Jin, Tracy E Campbell, Lindsey M Draper, et al.
Journal for Immunotherapy of Cancer|September 27, 2023
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomicsCatherine M Ade, Matthew J Sporn, Sudipto Das, et al.
European Journal of Immunology|July 20, 2024
Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Malcolm J W Sim, Ken-Ichi Hanada, Zachary Stotz, et al.
Pageof 9